CVS Health (CVS) Tops Q2 EPS by 20c, Raises FY Guidance

CVS Health (NYSE: CVS) reported Q2 EPS of $1.89, $0.20 better than the analyst estimate of $1.69. Revenue for the quarter came in at $63.4 billion versus the consensus estimate of $62.65 billion.

GUIDANCE:

CVS Health sees FY2019 EPS of $6.89-$7.00, versus the consensus of $6.83.

• Confirmed GAAP operating income guidance range of $11.8 billion to $12.0 billion
• Raised the guidance range for adjusted operating income (1) to $15.2 billion to $15.4 billion from $15.0 billion to $15.2 billion
• Raised and narrowed GAAP diluted EPS from continuing operations guidance range to $4.93 to $5.04 from $4.90 to $5.05
• Raised and narrowed Adjusted EPS (2) guidance range to $6.89 to $7.00 from $6.75 to $6.90
• Raised cash flow from operations guidance range to $10.1 billion to $10.6 billion from $9.8 billion to $10.3 billion

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• Canaccord Reiterates Buy Rating on Seer Inc. (SEER)
• Innovative Eyewear posts 71% sales gain, adds retail partners